MA40057A - Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants - Google Patents

Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants

Info

Publication number
MA40057A
MA40057A MA040057A MA40057A MA40057A MA 40057 A MA40057 A MA 40057A MA 040057 A MA040057 A MA 040057A MA 40057 A MA40057 A MA 40057A MA 40057 A MA40057 A MA 40057A
Authority
MA
Morocco
Prior art keywords
skin
therapeutic
tratment
abnormal skin
microorganisms
Prior art date
Application number
MA040057A
Other languages
English (en)
Inventor
Azim Momin Munivar
Travis Michael Whitfill
Original Assignee
Azitra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azitra filed Critical Azitra
Publication of MA40057A publication Critical patent/MA40057A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)

Abstract

La présente invention concerne des méthodes de traitement ou de prévention d'états cutanés anormaux chez un homme en ayant besoin, comprenant l'administration d'une composition de culture cellulaire qui comporte une culture vivante de bactéries incluant au moins une souche génétiquement modifiée qui produit un polypeptide recombinant pour le traitement thérapeutique dudit état cutané anormal. L'invention concerne également des compositions pharmaceutiques contenant, en tant que principes actifs, des microorganismes génétiquement modifiés exprimant des polypeptides thérapeutiques recombinants pharmacologiquement actifs non vaccinogènes, en vue de traiter ou de prévenir des états cutanés anormaux.
MA040057A 2014-05-30 2015-05-28 Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants MA40057A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462005558P 2014-05-30 2014-05-30
US201462005652P 2014-05-30 2014-05-30

Publications (1)

Publication Number Publication Date
MA40057A true MA40057A (fr) 2015-12-03

Family

ID=54699800

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040057A MA40057A (fr) 2014-05-30 2015-05-28 Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants

Country Status (6)

Country Link
US (3) US10702558B2 (fr)
EP (2) EP4144756A1 (fr)
JP (2) JP6810028B2 (fr)
ES (1) ES2929579T3 (fr)
MA (1) MA40057A (fr)
WO (1) WO2015184134A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2929579T3 (es) 2014-05-30 2022-11-30 Azitra Inc Tratamiento terapéutico de enfermedades cutáneas con microorganismos cutáneos comensales recombinantes
EP3448398A4 (fr) 2016-04-21 2019-12-18 Naked Biome, Inc. Compositions et méthodes pour le traitement de troubles cutanés
EP4740954A3 (fr) * 2017-06-16 2026-08-05 Azitra, Inc. Compositions et procédés pour le traitement du syndrome de netherton avec des micro-organismes recombinants exprimant lekti
US20210177917A1 (en) * 2017-08-31 2021-06-17 The Regents Of The University Of California Molecular bacteriotherapy to control skin enzymatic activity
EP3678640A4 (fr) * 2017-09-05 2021-06-09 Azitra, Inc. Procédés et compositions pour traiter une maladie cutanée inflammatoire
MX2020005875A (es) 2017-12-05 2020-10-08 Bioplx Inc Métodos y composiciones para prevenir la infección microbiana.
JP7121969B2 (ja) * 2018-02-23 2022-08-19 株式会社北里コーポレーション 培養液保護用液状物
KR102958724B1 (ko) * 2018-04-05 2026-05-06 아지트라 인코포레이티드 재조합 미생물을 사용하여 피부 질환을 치료하기 위한 방법 및 조성물
AU2019203692B2 (en) * 2018-08-30 2024-12-12 Kenvue Brands Llc Topical composition containing glycerin and yeast extract
EP3856914A1 (fr) * 2018-09-26 2021-08-04 Krystal Biotech, Inc. Compositions et procédés pour le traitement de maladies de la peau
WO2020076770A1 (fr) * 2018-10-08 2020-04-16 Yale University Liaison et agrégation sélectives de kératine humaine dans la barrière cutanée à l'aide de sous-domaines de filaggrine humaine sd67 et sd150
KR20260040113A (ko) 2018-11-16 2026-03-23 아지트라 인코포레이티드 스타필로코쿠스 박테리아의 영양요구성 균주
CZ308231B6 (cs) * 2019-02-11 2020-03-11 BiomCare s.r.o. Kombinované několikastupňové mikrobiální přípravky a způsob jejich aplikace
CA3136115A1 (fr) * 2019-04-05 2020-10-08 Azitra Inc Procedes et compositions pour traiter une dermatite atopique avec des microorganismes recombinants
WO2020257519A1 (fr) * 2019-06-19 2020-12-24 Chan Zuckerberg Biohub, Inc. Bactéries conçues pour obtenir des lymphocytes t spécifiques à un antigène
US20230087622A1 (en) * 2020-01-29 2023-03-23 The Jackson Laboratory Bacterial admixtures
EP4232053A4 (fr) * 2020-10-21 2025-05-21 The Jackson Laboratory Biocapteurs antimicrobiens
EP4274435A1 (fr) * 2021-01-05 2023-11-15 Lactobio A/S Souches, compositions et méthodes d'utilisation
JPWO2023063314A1 (fr) * 2021-10-11 2023-04-20

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0637384B2 (ja) * 1985-09-21 1994-05-18 株式会社資生堂 皮膚化粧料
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
DE4221255C2 (de) 1992-06-26 1994-09-15 Lancaster Group Ag Phospholipide enthaltendes Kosmetikum
DE4221268C2 (de) 1992-06-26 1997-06-12 Lancaster Group Ag Verwendung eines Dermatikums zur Unterstützung des Sauerstofftransportes in der Haut
NO2480669T3 (fr) * 2009-09-25 2018-04-07
NO2504357T3 (fr) 2009-11-23 2017-12-30
US20130078275A1 (en) * 2010-05-25 2013-03-28 The Board Of Trustees Of The University Of Illinois Novel systems, vectors, and methods for delivery of biomolecules to eukaryotic cells
EP2882494A1 (fr) * 2012-08-07 2015-06-17 Topgenix Inc. Composition topique comprenant des bactéries transformées exprimant un composé d'intérêt
KR101491240B1 (ko) 2013-03-15 2015-02-11 현대자동차주식회사 인비저블 슬라이딩 도어 링크 구조
ES2929579T3 (es) 2014-05-30 2022-11-30 Azitra Inc Tratamiento terapéutico de enfermedades cutáneas con microorganismos cutáneos comensales recombinantes

Also Published As

Publication number Publication date
WO2015184134A1 (fr) 2015-12-03
US10702558B2 (en) 2020-07-07
JP6810028B2 (ja) 2021-01-06
JP2017518370A (ja) 2017-07-06
ES2929579T3 (es) 2022-11-30
EP3148569B1 (fr) 2022-07-06
JP2021038271A (ja) 2021-03-11
EP3148569A1 (fr) 2017-04-05
US20210379120A1 (en) 2021-12-09
US20250009810A1 (en) 2025-01-09
US12036248B2 (en) 2024-07-16
EP3148569A4 (fr) 2017-11-22
CA2979079A1 (fr) 2015-12-03
EP4144756A1 (fr) 2023-03-08
US20180161380A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
MX2018005588A (es) Terapia de sustitucion de plasminogeno para la deficiencia de plasminogeno.
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MY189333A (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
EP4124346A3 (fr) Compositions et procédés de traitement de maladies
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
MX2020000083A (es) Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX357071B (es) Medicamentos que comprenden apolipoproteína a-iv no glicosilada para el tratamiento de diabetes.
PH12019501439A1 (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
EP4361634A3 (fr) Méthodes de traitement et de surveillance de l'état du cancer
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
GB2537783A (en) Methods and compositions used in treating inflammatory and autoimmune diseases
MD20180049A2 (ro) Compoziţie farmaceutică
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
IN2013MN01547A (fr)
MX2016011002A (es) Tratamiento de angioedema hereditario con inhibidor c1.